Panomics reveals patient individuality as the major driver of colorectal cancer progression.
Biomarkers
Colorectal cancer
Metastasis
Panomics
Patient individuality
Tumour heterogeneity
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
23 01 2023
23 01 2023
Historique:
received:
22
10
2022
accepted:
26
12
2022
entrez:
23
1
2023
pubmed:
24
1
2023
medline:
26
1
2023
Statut:
epublish
Résumé
Colorectal cancer (CRC) is one of the most prevalent cancers, with over one million new cases per year. Overall, prognosis of CRC largely depends on the disease stage and metastatic status. As precision oncology for patients with CRC continues to improve, this study aimed to integrate genomic, transcriptomic, and proteomic analyses to identify significant differences in expression during CRC progression using a unique set of paired patient samples while considering tumour heterogeneity. We analysed fresh-frozen tissue samples prepared under strict cryogenic conditions of matched healthy colon mucosa, colorectal carcinoma, and liver metastasis from the same patients. Somatic mutations of known cancer-related genes were analysed using Illumina's TruSeq Amplicon Cancer Panel; the transcriptome was assessed comprehensively using Clariom D microarrays. The global proteome was evaluated by liquid chromatography-coupled mass spectrometry (LC‒MS/MS) and validated by two-dimensional difference in-gel electrophoresis. Subsequent unsupervised principal component clustering, statistical comparisons, and gene set enrichment analyses were calculated based on differential expression results. Although panomics revealed low RNA and protein expression of CA1, CLCA1, MATN2, AHCYL2, and FCGBP in malignant tissues compared to healthy colon mucosa, no differentially expressed RNA or protein targets were detected between tumour and metastatic tissues. Subsequent intra-patient comparisons revealed highly specific expression differences (e.g., SRSF3, OLFM4, and CEACAM5) associated with patient-specific transcriptomes and proteomes. Our research results highlight the importance of inter- and intra-tumour heterogeneity as well as individual, patient-paired evaluations for clinical studies. In addition to changes among groups reflecting CRC progression, we identified significant expression differences between normal colon mucosa, primary tumour, and liver metastasis samples from individuals, which might accelerate implementation of precision oncology in the future.
Sections du résumé
BACKGROUND
Colorectal cancer (CRC) is one of the most prevalent cancers, with over one million new cases per year. Overall, prognosis of CRC largely depends on the disease stage and metastatic status. As precision oncology for patients with CRC continues to improve, this study aimed to integrate genomic, transcriptomic, and proteomic analyses to identify significant differences in expression during CRC progression using a unique set of paired patient samples while considering tumour heterogeneity.
METHODS
We analysed fresh-frozen tissue samples prepared under strict cryogenic conditions of matched healthy colon mucosa, colorectal carcinoma, and liver metastasis from the same patients. Somatic mutations of known cancer-related genes were analysed using Illumina's TruSeq Amplicon Cancer Panel; the transcriptome was assessed comprehensively using Clariom D microarrays. The global proteome was evaluated by liquid chromatography-coupled mass spectrometry (LC‒MS/MS) and validated by two-dimensional difference in-gel electrophoresis. Subsequent unsupervised principal component clustering, statistical comparisons, and gene set enrichment analyses were calculated based on differential expression results.
RESULTS
Although panomics revealed low RNA and protein expression of CA1, CLCA1, MATN2, AHCYL2, and FCGBP in malignant tissues compared to healthy colon mucosa, no differentially expressed RNA or protein targets were detected between tumour and metastatic tissues. Subsequent intra-patient comparisons revealed highly specific expression differences (e.g., SRSF3, OLFM4, and CEACAM5) associated with patient-specific transcriptomes and proteomes.
CONCLUSION
Our research results highlight the importance of inter- and intra-tumour heterogeneity as well as individual, patient-paired evaluations for clinical studies. In addition to changes among groups reflecting CRC progression, we identified significant expression differences between normal colon mucosa, primary tumour, and liver metastasis samples from individuals, which might accelerate implementation of precision oncology in the future.
Identifiants
pubmed: 36691026
doi: 10.1186/s12967-022-03855-0
pii: 10.1186/s12967-022-03855-0
pmc: PMC9869555
doi:
Substances chimiques
RNA
63231-63-0
Biomarkers, Tumor
0
SRSF3 protein, human
0
Serine-Arginine Splicing Factors
170974-22-8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
41Informations de copyright
© 2023. The Author(s).
Références
Cell. 2017 Feb 9;168(4):613-628
pubmed: 28187284
Ann Transl Med. 2020 Feb;8(4):96
pubmed: 32175389
DNA Cell Biol. 2012 Jan;31(1):43-9
pubmed: 22011044
Genomics. 1998 Dec 1;54(2):200-14
pubmed: 9828122
Cancer. 2015 May 15;121(10):1570-80
pubmed: 25603912
BMC Bioinformatics. 2009 May 27;10:161
pubmed: 19473525
J Cell Sci. 2009 Apr 1;122(Pt 7):995-1004
pubmed: 19295126
Science. 2017 Aug 18;357(6352):
pubmed: 28818916
J Pers Med. 2022 Jan 18;12(2):
pubmed: 35207616
Cell Commun Signal. 2017 Oct 3;15(1):38
pubmed: 28974231
BMC Cancer. 2015 Oct 12;15:679
pubmed: 26459317
J Hematol Oncol. 2020 Sep 3;13(1):119
pubmed: 32883331
Br J Cancer. 2012 May 22;106(11):1875-80
pubmed: 22555397
Gut. 2001 May;48(5):623-9
pubmed: 11302958
PLoS One. 2013 Apr 12;8(4):e60861
pubmed: 23593331
Nat Rev Clin Oncol. 2018 Jun;15(6):353-365
pubmed: 29599476
Langenbecks Arch Surg. 2008 Jan;393(1):13-9
pubmed: 17909846
Nat Rev Clin Oncol. 2019 Apr;16(4):256-268
pubmed: 30487530
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Mol Cell Proteomics. 2013 Aug;12(8):2324-31
pubmed: 23589346
Br J Cancer. 1995 Apr;71(4):868-72
pubmed: 7710956
Nat Med. 2015 Nov;21(11):1350-6
pubmed: 26457759
Genome Res. 2018 Nov;28(11):1747-1756
pubmed: 30341162
DNA Cell Biol. 2001 Jun;20(6):331-8
pubmed: 11445004
Nucleic Acids Res. 2017 Jan 4;45(D1):D1100-D1106
pubmed: 27924013
Genes Chromosomes Cancer. 2007 Jan;46(1):10-26
pubmed: 17044061
BMC Cancer. 2005 Apr 18;5:41
pubmed: 15836783
J Clin Lab Anal. 1991;5(5):344-66
pubmed: 1941355
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
RNA. 2019 May;25(5):630-644
pubmed: 30796096
Oncogene. 2014 Mar 13;33(11):1407-17
pubmed: 23503458
Gastroenterology. 2009 Jul;137(1):15-7
pubmed: 19450592
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
JAMA Oncol. 2018 Aug 1;4(8):1093-1098
pubmed: 29710180
Differentiation. 1993 Jun;53(2):67-74
pubmed: 8359594
Oncotarget. 2017 Jul 4;8(33):54939-54950
pubmed: 28903393
Semin Oncol. 2005 Dec;32(6 Suppl 9):S109-11
pubmed: 16399446
Nat Protoc. 2007;2(8):1896-906
pubmed: 17703201
Front Oncol. 2020 May 07;10:560
pubmed: 32457828
Nat Protoc. 2016 Dec;11(12):2301-2319
pubmed: 27809316
Cancer Cell Int. 2020 Apr 10;20:120
pubmed: 32308565
Clin Cancer Res. 2010 Aug 1;16(15):4046-56
pubmed: 20562209
Int J Biochem Cell Biol. 2011 Mar;43(3):320-30
pubmed: 21163365
Int J Cancer. 2014 Jun 1;134(11):2513-22
pubmed: 23852704
PLoS One. 2014 Apr 01;9(4):e93469
pubmed: 24691449
Pathol Oncol Res. 2008 Mar;14(1):15-22
pubmed: 18386166
Exp Cell Res. 2006 Jun 10;312(10):1785-97
pubmed: 16566923
Cell. 2017 Feb 9;168(4):584-599
pubmed: 28187282
Front Oncol. 2020 Dec 18;10:634122
pubmed: 33392101
Nat Methods. 2009 May;6(5):359-62
pubmed: 19377485
Oncol Lett. 2017 Dec;14(6):6671-6677
pubmed: 29163694
Proteomics Clin Appl. 2019 Mar;13(2):e1800113
pubmed: 30790462
Int J Mol Sci. 2018 Oct 02;19(10):
pubmed: 30279379
Cochrane Database Syst Rev. 2015 Dec 10;(12):CD011134
pubmed: 26661580
Theranostics. 2022 Mar 6;12(6):2674-2686
pubmed: 35401834
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer Gene Ther. 2017 Jun;24(6):244-250
pubmed: 28409560
Cancers (Basel). 2021 Jan 05;13(1):
pubmed: 33466447
Anticancer Res. 2019 Apr;39(4):1661-1666
pubmed: 30952704
RNA. 2008 Dec;14(12):2538-49
pubmed: 18952824
J Proteome Res. 2019 Jan 4;18(1):1-6
pubmed: 30296097